CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 600 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05178212
NCT05178212N/ACompleted

Characteristics and Outcomes of Patients With COVID-19-related Acute Respiratory Failure Treated With High-flow Nasal Oxygen and Awake-prone Position

Hospital Privado de Comunidad de Mar del Plata·observational·Posted Jan 5, 2022·Updated Jan 27, 2026

In Brief

An observational study for COVID-19 and 4 related conditions. Completed, enrolled 600 participants across 1 site.

Detailed Summary

A subset of patients with COVID-19 develops acute respiratory failure and acute respiratory distress syndrome (ARDS) (1). The use of invasive mechanical ventilation for the treatment of these conditions is associated with high mortality rates (2,3). The use of high-flow nasal oxygen therapy (HFNO) and awake prone position (AW-PP) could to decrease the need for endotracheal intubation and other adverse clinical outcomes (4-6). The aim of this study is to evaluate the clinical results of the simultaneous application of high-flow nasal oxygen therapy HFNO and awake-prone position in a cohort of patients with severe respiratory failure secondary to COVID-19 on relevant clinical outcomes, and to assess risk factors of treatment failure defined as requirement of invasive mechanical ventilation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesArgentina

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 5, 2022
Enrollment StartApr 15, 2020
Primary CompletionDec 30, 2021
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.5 years ago